FCA Litigation Forecast: Bad News, Good News
Client Alert | less than 1 min read | 03.24.17
The FCA remains the federal government’s number one recovery tool, but how will that be impacted by recent developments in the case law and regulations? In a recent Westlaw Journal piece, C&M’s Brian Tully McLaughlin previews the impact of the Supreme Court’s landmark Escobar decision for defendants in all manner of FCA suits as well as the significant increases in the Act’s statutory penalties.
Contacts
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
